Open Access Open Access  Restricted Access Subscription Access

Objectives, Symptoms, Mechanism of Action, Administration, Adverse Effects, Contraindications, Monitoring, Toxicity and Enhancing Health Care Team Outcomes of Statin Medications

Muralinath E., Madhavi Latha C., Ramadevi Ch., Sheethal U., Guruprasad M., Karthik Jayanth Y., Renuka U., Sony Sharlet E.

Abstract


Statin medications are utilized regarding the management of hypercholesteremia. Statins are inhibitors of hydroxymethylglutaryl-CoA reductase enzyme and lower total cholesterol, low-density lipoprotein (LDL), and triglyceride concentrations. The FDA-approved statins are atorvastatin, rosuvastatin, simvastatin, pravastatin, fluvastatin, lovastatin, and pitavastatin. Individuals at high risk for atherosclerotic cardiovascular disease need more aggressive management strategies along with higher-intensity statin therapy. The mechanisms of action, dosage guidelines, clinical toxicology, possible drug interactions, pharmacokinetics, and monitoring techniques pertaining to healthcare practitioners' management of hypocholesteremia are reviewed by participating clinicians. The importance of coronary artery calcium scoring in unclear conditions is highlighted. The interprofessional team learns the optimal statin prescribing guidelines from this activity.


Full Text:

PDF

References


O'Malley, P. G., Arnold, M. J., Kelley, C., Spacek, L., Buelt, A., Natarajan, S., Donahue, M. P., Vagichev, E., Ballard-Hernandez, J., Logan, A., Thomas, L., Ritter, J., Neubauer, B. E., & Downs, J. R. (2020). Management of dyslipidemia for cardiovascular disease risk reduction: Synopsis of the 2020 updated U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. Annals of Internal Medicine, 173(10), 822–829. https://doi.org/10.7326/M20-4850

Strilchuk, L., Tocci, G., Fogacci, F., & Cicero, A. F. G. (2020). An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. Expert Opinion on Pharmacotherapy, 21(5), 531–539. https://doi.org/10.1080/14656566.2020.1721468

Koopal, C., Marais, A. D., & Visseren, F. L. (2017). Familial dysbetalipoproteinemia: An underdiagnosed lipid disorder. Current Opinion in Endocrinology, Diabetes and Obesity, 24(2), 133–139. https://doi.org/10.1097/MED.0000000000000315

Rygiel, K. (2018). Hypertriglyceridemia—Common causes, prevention and treatment strategies. Current Cardiology Reviews, 14(1), 67–76. https://doi.org/10.2174/1573403X13666171019153834

van Rosendael, A. R., van den Hoogen, I. J., Gianni, U., Ma, X., Tantawy, S. W., Bax, A. M., Lu, Y., Andreini, D., Al-Mallah, M. H., Budoff, M. J., Cademartiri, F., Chinnaiyan, K., Choi, J. H., Conte, E., Marques, H., de Araújo Gonçalves, P., Gottlieb, I., Hadamitzky, M., Leipsic, J. A., ... Chang, H. J. (2021). Association of statin treatment with progression of coronary atherosclerotic plaque composition. JAMA Cardiology, 6(11), 1257–1266. https://doi.org/10.1001/jamacardio.2021.3055

Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., Goldberg, R., Heidenreich, P. A., Hlatky, M. A., Jones, D. W., Lloyd-Jones, D. M., Lopez-Pajares, N., Ndumele, C. E., Orringer, C. E., Peralta, C. A., ... Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation, 139(25), e1082–e1143. https://doi.org/10.1161/CIR.0000000000000625

Amarenco, P., & Tonkin, A. M. (2004). Statins for stroke prevention: Disappointment and hope. Circulation, 109(23 Suppl. 1), III44–III49. https://doi.org/10.1161/01.CIR.0000131514.17795.9F

Luirink, I. K., Wiegman, A., Kusters, D. M., Hof, M. H., Groothoff, J. W., de Groot, E., Kastelein, J. J. P., & Hutten, B. A. (2019). 20-year follow-up of statins in children with familial hypercholesterolemia. The New England Journal of Medicine, 381(16), 1547–1556. https://doi.org/10.1056/NEJMoa1816454

McGowan, M. P., Hosseini Dehkordi, S. H., Moriarty, P. M., & Duell, P. B. (2019). Diagnosis and treatment of heterozygous familial hypercholesterolemia. Journal of the American Heart Association, 8(24), e013225. https://doi.org/10.1161/JAHA.119.013225

Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023). AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 77(5), 1797–1835. https://doi.org/10.1097/HEP.0000000000000323

Asleh, R., Briasoulis, A., Pereira, N. L., Boilson, B. A., Edwards, B. S., Adigun, R., Maltais, S., Daly, R. C., Lerman, A., & Kushwaha, S. S. (2018). Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients. ESC Heart Failure, 5(6), 1118–1129. https://doi.org/10.1002/ehf2.12345

Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., Kazi, D. S., Kolte, D., Kumbhani, D. J., LoFaso, J., Mahtta, D., Mark, D. B., Minissian, M., Navar, A. M., Patel, A. R., ... Williams, M. S. (2023). 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease. Circulation, 148(9), e9–e119. https://doi.org/10.1161/CIR.0000000000001168

Sirtori, C. R. (2014). The pharmacology of statins. Pharmacological Research, 88, 3–11. https://doi.org/10.1016/j.phrs.2014.03.002

Kavalipati, N., Shah, J., Ramakrishan, A., & Vasnawala, H. (2015). Pleiotropic effects of statins. Indian Journal of Endocrinology and Metabolism, 19(5), 554–562. https://doi.org/10.4103/2230-8210.163106

Climent, E., Benaiges, D., & Pedro-Botet, J. (2021). Hydrophilic or lipophilic statins? Frontiers in Cardiovascular Medicine, 8, 687585. https://doi.org/10.3389/fcvm.2021.687585

Filppula, A. M., Hirvensalo, P., Parviainen, H., Ivaska, V. E., Lönnberg, K. I., Deng, F., Viinamäki, J., Kurkela, M., Neuvonen, M., & Niemi, M. (2021). Comparative hepatic and intestinal metabolism and pharmacodynamics of statins. Drug Metabolism and Disposition, 49(8), 658–667. https://doi.org/10.1124/dmd.121.000403

Egom, E. E., & Hafeez, H. (2016). Biochemistry of statins. Advances in Clinical Chemistry, 73, 127–168. https://doi.org/10.1016/bs.acc.2015.10.001

Wessler, J. D., Grip, L. T., Mendell, J., & Giugliano, R. P. (2013). The P-glycoprotein transport system and cardiovascular drugs. Journal of the American College of Cardiology, 61(25), 2495–2502. https://doi.org/10.1016/j.jacc.2013.02.058

Wiggins, B. S., Saseen, J. J., Page, R. L., Reed, B. N., Sneed, K., Kostis, J. B., Lanfear, D., Virani, S. S., & American Heart Association Clinical Pharmacology Committee. (2016). Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: A scientific statement from the American Heart Association. Circulation, 134(21), e468–e495. https://doi.org/10.1161/CIR.0000000000000456

Stone, N. J., Greenland, P., & Grundy, S. M. (2022). Statin usage in primary prevention: Comparing the USPSTF recommendations with the AHA/ACC/multisociety guidelines. JAMA Cardiology, 7(10), 997–999. https://doi.org/10.1001/jamacardio.2022.2738


Refbacks

  • There are currently no refbacks.